Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0)
# 4963
Out of 5,270 analysts
43
Total ratings
14.29%
Success rate
-33.29%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Prothena Corp | Reiterates: Overweight | n/a | n/a | n/a | 1 | Feb 21, 2025 | |
CRISPR Therapeutics | Reiterates: Neutral | n/a | n/a | n/a | 4 | Feb 19, 2025 | |
Cidara Therapeutics | Assumes: Overweight | n/a | n/a | n/a | 1 | Jan 27, 2025 | |
Incyte | Reiterates: Neutral | n/a | n/a | n/a | 6 | Jan 10, 2025 | |
Agios Pharmaceutical... | Reiterates: Overweight | n/a | n/a | n/a | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 96 96 | 29.2 | 228.77% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | n/a | n/a | n/a | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 292 292 | 141.77 | 105.97% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 370 | 483.3 | -23.44% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 31 | n/a | n/a | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | May 30, 2017 |